IL-22 is increased in the tumor of patients with non-small cell lung cancer (NSCLC), pancreatic cancer, gastric cancer and hepatocellular carcinoma and predicts a poor prognosis, higher disease stage, and faster tumor progression (120–123). Here, IL22 is linked to non-small cell lung carcinoma.